ERBB2 and breast cancer: The efficacy of olaparib was even more profound in the OlympiA study, where statistically significant improvements in median invasive and distant disease-free survival and OS were observed in patients with HER2-negative, high-risk early BC treated with adjuvant olaparib compared with those who received placebo, further suggesting that earlier treatment with olaparib results in improved efficacy [24, 25].